Conference Day One
Wednesday 26th February 2025
8:00 am Morning Check in & Coffee
8:50 am Chair’s Opening Remarks
Understanding Unique Characteristics of an Optimal Radiopharmaceutical Target to Guide Ideal Selection
9:00 am Panel Discussion: Investigating Attributes of a Prime Radiopharmaceutical Target to Match the Properties of a Radioactive Drug
Synopsis
- Considering receptor density, expression levels and radiosensitive tissues
- Analyzing alpha vs beta emitter target requirements for optimal strategy
- Assessing stromal targeting such as FAP or internalized targets
9:30 am uPAR: A Promising Novel Radiopharmaceutical Target for Solid Tumors
Synopsis
- Revealing why uPAR is a promising radiopharma target and what characteristics make it particularly appealing
- Sharing the strategy that went into creating Monopar’s targeting agent against uPAR
- Optimizing biodistribution preclinically and how that translated
10:00 am Simplifying & Diversifying the Toolkits to Evaluate the Targeting Efficiency & Early Preclinical Dosimetry of Novel TRPs
Synopsis
- When testing new TRPs on a preclinical stage, time and quantity matter
- Exploring new technologies allowing for more diverse testing methods in PK analysis, with accurate results in shorter experimental times
- Outlining available tools, their benefits and limitations and CROs statistical analysis of what pharma companies choose for their PK studies
10:10 am Disclosing Novel Radiopharmaceutical Therapeutic Target Beyond Current Pipeline
Synopsis
- Identifying key target attributes
- Revealing targeting strategies
- Uncovering early preclinical data
10:40 am Speed Networking & Morning Coffee Break
Mining New Radiopharmaceutical Targets for Novel Therapeutics to Differentiate Your Pipeline
11:40 am Leveraging Novel Proteogenomic Approaches & Machine Learning to Accelerate Radioconjugate Target Discovery
Synopsis
- Identifying and validating therapeutic targets using surface proteomics and tailored data analytics
- Integration of surface proteomics into proteogenomic computational methods to enhance target selection paired with patient, disease and drug biology
- Exploring the “deep proteome” and other proteomic data types to unlock novel target space
12:10 pm Unveiling Key Regulatory Elements of the TGFB-LRRC15 Axis Through Advanced High-Throughput Screening Methodologies
Synopsis
- Uncovering TGFβ)-driven and LRRC15+ signature associated immunotherapy resistance
- Targeting LLRC15 for therapeutic and imaging
- Overcoming radio resistance through enhanced mechanistic understandings
12:40 pm Lunch Break & Networking
Selecting Characterized & Novel Targets for Use with Radiopharmaceutical Candidates to Address Unmet Medical Need
1:40 pm Fireside: Paving the Path for Novel Radiopharmaceutical Targets or Following Bonified ADC Targets: Advantages & Pitfalls
Synopsis
- Leveraging established ADC Targets for radiopharmaceuticals for well characterized mechanism of action such as NECTIN-4
- Identifying and pursuing untapped biological targets to revolutionize radiopharmaceuticals such as failed ADC targets
- Commercial considerations to balance risks and hurdles
2:10 pm Revealing Novel Radioimmunotherapy Targeting B7-H3 for Solid Tumors
Synopsis
- Targeting the immune checkpoint protein selectively expressed
- Understanding the complex tumor microenvironment
- Delivering localized radiation
2:40 pm Strategy & Rationale Behind Selection of RPT Targets: Case Studies with GPC3 & CAIX
Synopsis
- Designing novel radiopharmaceutical drugs with precision
- Sharing design choices for enhanced efficacy
3:10 pm Afternoon Coffee Break & Poster Session
Synopsis
Take a break from the main presentations to learn from your peers. Explore our scientific poster session to share your work or hear from others. Inquire with the Hanson Wade team to submit your poster.
Rational Drug Design for Radiopharmaceuticals – Targeting Strategies
3:30 pm Exploring Chemical Strategies to Expand the Therapeutic Window for Targeted Radiotherapies
Synopsis
- Discussing new approaches to the delivery of radioisotopes to tumors
- Designing molecules with enhanced tumor uptake and retention
4:10 pm Linker Design Trends & Implications for Enhanced Radiopharmaceutical Agents’ PD/PK
Synopsis
- Covering the latest trends and innovations in linker design
- Appreciating implications for radiopharmaceutical properties
- Exploring strategies include plasma protein binding, covalent binding, charge and hydrophobicity, and enzymatic cleavage
4:40 pm Roundtable Discussion: Assessing Targeting Moieties to Match Target & Disease Characteristics
Synopsis
- Evaluating isotope half-life and desired circulation time
- Exploring varying options for targeting: small molecule, peptide, antibody, engineered antibodies, antibody fragments, mini proteins and more
- Appreciating differences in potential toxicities with each approach